Last reviewed · How we verify
Mucopolysaccharidosis, MPS-IV-A
Approved treatments
- Rhgalns · BioMarin
VIMIZIM provides exogenous N-acetylgalactosamine-6-sulfatase to increase the catabolism of GAGs KS and C6S in lysosomes.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Mucopolysaccharidosis, MPS-IV-A patent landscape — cliff calendar, originator estates, attackable patents
- Mucopolysaccharidosis, MPS-IV-A treatment landscape brief
- Mucopolysaccharidosis, MPS-IV-A treatment updates RSS
Frequently asked questions about Mucopolysaccharidosis, MPS-IV-A
What drugs treat Mucopolysaccharidosis, MPS-IV-A?
Tracked treatments include Rhgalns.
What is the treatment for Mucopolysaccharidosis, MPS-IV-A?
Standard treatment for Mucopolysaccharidosis, MPS-IV-A includes Rhgalns. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Mucopolysaccharidosis, MPS-IV-A patent cliff · Mucopolysaccharidosis, MPS-IV-A CI report
- Treatment: Rhgalns · BioMarin
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing